Cargando…
Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
Effective treatments and vaccines against COVID-19 used in clinical practice have made a positive impact on controlling the spread of the pandemic, where they are available. Nevertheless, even if fully vaccinated, immunocompromised patients still remain at high risk of adverse outcomes. This has dri...
Autores principales: | Akinosoglou, Karolina, Rigopoulos, Emmanouil-Angelos, Kaiafa, Georgia, Daios, Stylianos, Karlafti, Eleni, Ztriva, Eleftheria, Polychronopoulos, Georgios, Gogos, Charalambos, Savopoulos, Christos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866621/ https://www.ncbi.nlm.nih.gov/pubmed/36680160 http://dx.doi.org/10.3390/v15010118 |
Ejemplares similares
-
Remdesivir Use in the Real-World Setting: An Overview of Available Evidence
por: Akinosoglou, Karolina, et al.
Publicado: (2023) -
Diabetic Patient Adherence to Yearly Influenza Vaccination in Northern Greece
por: Pilalas, Dimitrios, et al.
Publicado: (2022) -
Coagulation Profile of COVID-19 Patients
por: Kaiafa, Georgia, et al.
Publicado: (2022) -
Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022) -
Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)